![Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay](https://consumer.healthday.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNzg5NjkyNS9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTcwMjkwNTE5NH0.DEzsb9DvZsqnlMPIb-oTqh13ZkYxwPuofRpc2YMm-Qg/image.jpg?width=1245&height=700&quality=85&coordinates=0%2C91%2C0%2C92)
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay
![Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-022-02826-6/MediaObjects/13075_2022_2826_Fig1_HTML.png)
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
![Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating](https://ard.bmj.com/content/annrheumdis/69/9/1629/F1.large.jpg)
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating
![Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2474-15-177/MediaObjects/12891_2014_Article_2118_Fig2_HTML.jpg)
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study | BMC Musculoskeletal Disorders | Full Text
![Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica](https://www.medicaljournals.se/acta/content_files/files/web/4415-web-resources/image/4415Fig1_fmt.png)
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens | HTML | Acta Dermato-Venereologica
![Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/bb3b76c5-4126-4951-ab23-1ae03c4a6d0f/bcpt_452_f1.gif)
Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
![Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1568997206000243-gr1.jpg)
Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect
![Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/64149bae-86ee-4d1d-92a7-98c8f7996536/gr1.gif)
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
![Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology](https://www.thelancet.com/cms/asset/3a9208df-2d8d-4b03-81bd-213a9a70aaa9/gr2.jpg)
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
![PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration](https://i1.rgstatic.net/publication/295503309_Effectiveness_of_two_different_doses_of_rituximab_for_the_treatment_of_rheumatoid_arthritis_in_an_international_cohort_Data_from_the_CERERRA_collaboration/links/577260c608aeef01a0b629ab/largepreview.png)
PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration
![VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2021/02/2MM_2.7.2021_3_RA-scaled.jpg)